Key Highlights
- Novo shares closed 7.7 percent lower, their worst single day since February, after the company's Long-term Growth targets failed to reassure investors.
- The company aims to launch more than five drugs with multi-blockbuster potential by 2030 and generate over 150 billion Danish kroner in Risk-adjusted pipeline sales by 2035.
- Semaglutide, the active ingredient in Wegovy and Ozempic, is set to lose key US Patent exclusivity starting in 2032, a market that accounted for more than half of Novo's sales last year.
- The company is moving beyond its traditional focus on obesity and diabetes, targeting new growth areas including blood and endocrine disorders, liver disease and cardiovascular disease.
Long-Term Targets Fail to Reassure
Novo shares fell sharply after the company's new long-term growth targets failed to ease investor concerns about its ability to compete in the increasingly crowded weight-loss market it helped pioneer. The Danish drugmaker said it aims to launch more than five drugs with multi-blockbuster potential by 2030 and generate more than 150 billion Danish kroner, roughly USD 23 billion, in risk-adjusted pipeline sales by 2035, including current assets. Shares closed 7.7 percent lower on the day, their worst single-day performance since February.
The company also said it expects Revenue growth between 2026 and 2030 to be broadly in line with a group of industry peers, a target some investors saw as signaling slower growth than they had historically come to expect from Novo.
The Patent Cliff Ahead
Novo's chief executive Mike Doustdar told investors at the company's Capital Markets Day in London that the central issue on most people's minds was that semaglutide, the active ingredient in Wegovy and Ozempic, will lose key patent exclusivity in the United States starting in 2032, a market that accounted for more than half of Novo's overall sales last year. Doustdar acknowledged the company had created an attractive market that nearly every other pharmaceutical company is now trying to enter, and said Novo needs to be prepared for that competition.
A Pivot Toward Diversification
Doustdar laid out plans to diversify the company's portfolio beyond its traditional focus areas, saying Novo intends to build out its Business around blood and endocrine disorders, liver disease and cardiovascular disease, while stating obesity and diabetes will remain the company's foundation. He said Novo will also become more active in business development going forward.
The pivot marks a notable shift from the strategy Doustdar outlined after becoming chief executive last year, when the company had initially sharpened its focus on its core obesity and diabetes franchises and moved away from broader expansion.
Competitive Pressure From Eli Lilly
Ahead of Monday's announcement, Novo shares had fallen 27 percent over the past 12 months, while shares of chief rival Eli Lilly had gained 52 percent over the same period. Lilly has captured a majority share of the injectable GLP-1 market despite launching its competing drugs years after Novo's products reached the market. While Novo's Wegovy pill launched successfully in the US earlier this year, it still represents a comparatively small portion of the company's total sales as it begins rolling out in additional markets.
A Year of Setbacks
A series of clinical setbacks and Leadership changes over the past year have compounded investor concerns. Last week, the company announced it is rebranding from Novo Nordisk to Novo and updating its corporate culture, a change Doustdar described as part of the same broader package intended to help the company compete more effectively against Lilly.
Outlook
Novo's ability to execute on its Diversification strategy while managing the looming patent cliff will likely remain the central question for investors in the years ahead, with the company's next several product launches and any bolt-on acquisitions likely to serve as key indicators of whether the new strategy is gaining traction.






Please wait processing your request...